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Background: In 2001, the World Health Organization (WHO) has recommended the use of artemisinin-based
combination therapy (ACT) as the first-line treatment of uncomplicated malaria cases, as monotherapies had
become ineffective in many parts of the world. As a result, the Democratic Republic of Congo (DRC) withdrew
chloroquine (CQ) from its malaria treatment policy in 2002 and an artesunate (AS)-amodiaquine (AQ) combination
became the ACT of choice in DRC in 2005. AQ-resistance (AQR) has been reported in several parts of the
world and mutations in codons 72-76 of the Plasmodium falciparum chloroquine-resistance transporter (pfcrt)
gene have been strongly correlated with resistance, especially mutations encoding the SVMNT haplotype. This
haplotype was first identified in Southeast Asia and South America but was recently reported in two African
countries neighbouring DRC. These facts raised two questions: the first about the evolution of CQ resistance
(CQR) in DRC and the second about the presence of the SVMNT haplotype, which would compromise the
use of AQ as a partner drug for ACT.
Methods: A total of 213 thick blood films were randomly collected in 2010 from a paediatric clinic in Kinshasa, DRC.
Microscopy controls and real-time polymerase chain reaction (RT-PCR) were performed for Plasmodium species
identification. Haplotypes of the pfcrt gene were determined by sequencing.
Results: The K76T mutation was detected in 145 out of 198 P. falciparum-positive samples (73.2%). In these
145 resistant strains, only the CVIET haplotype was detected.
Conclusions: This study is the first to assess the molecular markers of resistance to CQ and AQ after the
introduction of ACT in DRC. The results suggest first that CQR is decreasing, as wild-type pfcrt haplotypes
were found in only 26.8% of the samples and secondly that the SVMNT haplotype is not yet present in
Kinshasa, suggesting that AQ remains valid as a partner drug for ACT in this region.
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In 2001, the World Health Organization (WHO) has
recommended the use of artemisinin-based combination
therapy (ACT) as the first-line treatment of uncompli-
cated malaria cases because monotherapies had become
ineffective in many parts of the world due to the spread
of Plasmodium falciparum strains resistant to almost all
anti-malarial drugs in use [1].
Resistance to chloroquine (CQ), the drug that had
been widely used for decades for malaria treatment [2],
has been well characterized and it is now established
that a mutation (K76T) occurring in the P. falciparum
chloroquine-resistance transporter (pfcrt) gene is the key
element [3-5]. Nevertheless many other mutations have
been described in this gene [6].
Childs and colleagues were the first to show in vitro
cross-resistance between amodiaquine (AQ) or its active
metabolite and CQ [7]. Because of their pharmacological
similarity, CQ and AQ were supposed to have the same
molecular mechanism of resistance. Furthermore, Ochong
et al., by analysing samples from a clinical trial held in
southern Sudan, demonstrated a link between the K76T
mutation and in vivo AQ resistance [8]. A few years later,
other studies performed on the pfcrt gene revealed that
some haplotypes defined by the aminoacids sequence at
positions 72-76 of the CRT protein were related to a par-
ticular resistance profile and also to a specific geographical
distribution. Sa et al. analysed reference strains and
provided the first in vitro evidence that one of these
haplotypes, the SVMNT (Ser-Val-Met-Asn-Thr), was
strongly correlated with resistance to desethylamodia-
quine (DEAQ), the active metabolite of AQ [9]. One year
later, in vivo evidence of this link has been given by Beshir
et al. who found that the presence of the SVMNT haplo-
type was sufficient to confer AQ resistance [10].
This haplotype was initially discovered in Asia and in
South America [11,12], but it has recently been found
in two African countries: first in Tanzania in 2006 [13],
then in 2010 in Angola [14]. Both countries border the
Democratic Republic of Congo (DRC), where CQ, after
being widely used, was officially abandoned in 2002 to be
replaced first by sulphadoxine-pyrimethamine (SP) and
then by an artesunate-amodiaquine (AS-AQ) combination
in 2005 [15].
This raised questions about the presence of the SVMNT
haplotype in the DRC, which would jeopardize the use of
AQ as a partner drug for ACT. These questions were
addressed in this study.
Methods
Sample collection
A total of 213 thin and thick blood films (TBF) were ran-
domly selected in April 2010 from the laboratory archives
of the St Marc Paediatric Clinic of Masina (Kinshasa). Allthe smears were positive using microscopic recordings as
selection criteria. The blood samples had been collected
between January and March 2010 from children under five
years who were suspected of malaria.
Malaria diagnosis
All blood smears underwent microscopic control per-
formed by two experienced microscopists and the results
were confirmed by real-time polymerase chain reaction
(RT-PCR).
DNA extraction
The whole TBF was used for DNA extraction, leaving the
thin smear for microscopic reading. Each TBF was first
immersed in xylene for 10 s to avoid contamination be-
tween samples and to dissolve any residual oil from previ-
ous microscopic examinations. Then it was scratched out
with a sterile scalpel as described previously by Cnops
et al. [16]. The scraped material was transferred into a
1.5 ml sterile Eppendorf tube containing 100 μl of PBS
and then used as a template for a semi-automated extrac-
tion using the Maxwell® 16 Cell LEV DNA purification Kit
(Promega, USA). A DNA internal extraction and inhib-
ition control was used to follow the extraction procedure
(DIAcontrolDNA®, Diagenode, Belgium). DNA was stored
at -20°C before processing.
Real-time PCR
The RT-PCR method for Plasmodium sp. identification
was used as previously described [17]. Briefly, a four-
primer PCR was used in two duplex reactions including a
couple of forward primers (Pfal + Pviv and Pmal + Pova)
with a universal reverse primer (plasmo2). The probes and
primers were designed to detect genes of the small sub-
unit 18S rRNA of Plasmodium species (Table 1). The mix
consisted of: 12.5 μl of 2X Taqman Universal PCR Master
Mix (Applied Biosystems, USA), 200 nM of all primers
and probes except P. vivax at 100 nM (primers and probe),
2.5 μl of Internal Control primers and probes and the rest
of water to make a total volume of 25 μl including 5 μl
of DNA. PCR tests were run on a 7500 Fast Instrument
(Applied Biosystems) and in the presence of positive
controls (provided by the Parasitology Unit, Institute
of Tropical Medicine, Antwerp and the Laboratory of
Clinical Microbiology, University Hospital of Liège). PCR
conditions were as follows: 2 min at 95°C, followed by
50 cycles of 15 s at 95°C and 60 s at 60°C.
Pfcrt genotyping
The procedure previously described by Ménard et al.
[18] was modified by adding an M13 fragment on the 5′
ends of the pfcrt primers (Table 1) to amplify a 154 bp
fragment that included the pfcrt codons in positions 72-
76 of all of the P. falciparum-positive samples. PCR tests
Table 1 Primer and probe sequences
RT-PCR Forward primer (plasmo1) Reverse primer (plasmo2) Probes






PCR/genotyping Forward primer Reverse primer
Pfcrt 5′-GTTCTTGTCTTGGTAAATGTGCTCA-3′ 5′-CAATT TTGTTTAAAGTTCTTTTAGCAA-3′
Legend: Pfal: P. falciparum; Pova: P.ovale; Pviv: P. vivax; Pmal: P. malariae; DQ: Darkquencher.
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USA) under the following conditions: 95°C for 10 min,
followed by 45 cycles of 20 s at 95°C and 45 s at 60°C.
Amplification was controlled on a microchip electrophor-
esis system using the MCE®-202 MultiNA (Shimadzu).
Amplicons were purified on Sciclone G3 Automated
Liquid Handling Workstation (Perkin Elmer, USA) using
AgencourtCleanSEQ® kit (Agencourt Bioscience, USA).
Sequencing was performed on a 3130xl DNA sequen-
cer (Applied Biosystems, USA).
Sequences were aligned using the GeneStudioTM®
Professional software and were compared with the refer-
ence sequence of the CRT protein [GenBank: CAD50842.1]
using the online BLASTx tool.
Ethical considerations
This study has received the ethical approbation of
the Ministry of Public Health of the DRC and of the




RT-PCR lead to the detection of 202/213 (93.4%) posi-
tive samples for P. falciparum including three mixed
infections (P. falciparum + Plasmodium malariae).
Pfcrt haplotypes
Pfcrt genotyping was successfully performed for 198
P. falciparum samples from the 202 positive samples
detected by RT-PCR. Among them, 145 K76T mutants
(73.2%) were detected and they were all harbouring the
CVIET haplotype. The wild strains had the CVMNK
haplotype. No other haplotypes were detected.
Discussion
Nearly ten years after the withdrawal of CQ in the first-
line treatment of malaria in the DRC, CQR strains re-
main above the warning threshold established by WHO.
However the prevalence of pfcrt 76 T mutants continues
to decline as shown in previous studies performed in DRCongo where a slow reversion in sensitivity has been
recorded. Indeed, the percentage of Pf resistant strains
went from 100% in 2000 [19], to 93% in 2002 [20],
83.8% in 2008 [21] and 73.2% in the present study. Fi-
nally, over the last ten years, the prevalence of resistant
strains has decreased by 26.8%. In other countries how-
ever, the decrease was much more significant like in
Malawi where CQR fell from 85% to 13% in 8 years [22]
after replacing CQ by SP or in Gabon with a drop of
55% (100% to 45%) in 6 years [23]. This fact could be
explained by the large area covered by DRC that is
more difficult to control, and by the relatively high cost
of ACT compared to former monotherapies, resulting
in a slower anti-malarial policy shift. Until 2007, CQ
was still the most widely used anti-malarial drug in
the DRC [24] although it was officially removed since
2002 and firstly replaced by SP. Aside from the effi-
ciency with which new drug policies were implemented,
malaria transmission intensity in the region and the use of
many other anti-malarial drugs in addition to the national
policy have been suggested to explain the difference in
trend [25].
The CVIET haplotype was the only resistant haplotype
identified in the present study. Indeed, it is the most
prevalent haplotype among the five discovered to date in
Africa and it seems that it has migrated from Southeast
Asia to Africa via India [26,27]. Some studies have de-
scribed this haplotype as a necessary but insufficient
condition to confer AQ resistance [28,29]. Beshir et al.
suggested that if the CVIET haplotype is highly preva-
lent, AQ can still be effective and further mutations on
the P. falciparum multidrug resistance gene (pfmdr1) are
required for the development of clinically significant AQ
resistance [10].
The only existing results on 72-76 pfcrt haplotypes that
are available for the DRC refer to samples collected in
2000. The study identified 100% of resistant strains and
these were distributed as follows: 14/27 (51.8%) SVIET,
12/27 (44.4%) CVIET and 1/27 (3.7%) of CVMNT [18].
Studies on a larger scale should be more representative of
the high prevalence of the SVIET haplotype, which
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found before only once, in a study performed in Papua
New Guinea [30].
Our results showed that the SVMNT haplotype is not
yet present in Kinshasa suggesting that AQ remains
valid as a partner drug for ACT. However, continuous
monitoring is necessary because, initially absent from
Africa, the SVMNT haplotype suddenly appeared in
Tanzania in 2004, where it was not present the year be-
fore [13]. This fact shows how the emergence of a new
haplotype can be spontaneous. This haplotype has been
also found recently in Angola by Gama et al. who sup-
posed that this haplotype may have been imported from
Brazil [14]. Frosch et al. showed that Angola and Tanzania
were among African countries where AQ was more exten-
sively used than in other countries during the last decade
[31]. This fact could have contributed to the selection of
SVMNT resistant strains, as suggested by Sa and by
others, who stipulated that AQ had a prominent role in
the selection of parasites carrying the SVMNT haplotype
[10,13,32,33]. In fact, SVMNT haplotype is predominant
in countries where AQ was early and widely used [32].
Malaria is a disease of great geographical diversity and,
as DRC is a very large country, the results of this study
concern only the region of Kinshasa and further studies
are needed.
Conclusion
This study confirms the slow reverse in sensitivity to CQ
in Kinshasa. This is the first to assess resistance to AQ
through pfcrt haplotypes after CQ withdrawal, especially
based on TBFs. AQ remains effective as a partner molecule
for ACT in Kinshasa but monitoring of P. falciparum
genomic resistance is mandatory.Abbreviations
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